Henry Siegfried

PHD Doctor of Philosophy,  Charité - Universitätsmedizin Berlin 

Location: Germany

Consulting Services

Hospital-Pharmacy-Insurance IT-Web-Mobile Technology Biostatistics

Areas Of Interest

gamma Aminobutyric Acid Agonists Orientation Program, Employee ELAVL2 protein Heart Defect, Congenital Taurochenodeoxycholate 6-alpha-Monooxygenase Tbp2 Transferrin-Binding Protein Cyproterone Acetate, (1 alpha,2 alpha)-Isomer Ru-24756 Nucleus, Lateral Tuberal Cancer of Mediastinum Phosphorylating Glyceraldehyde 3 Phosphate Dehydrogenase Manifestation, Oral Scotomas, Bjerrum Facilities, Waste Disposal Multiple Primary Neoplasm C1-set Domain, Immunoglobulin Antepsin Derivatives, Caproic Acid Promyelocyte Monieziases Inhibitors, CYP2C19 Hypothalamic Dysfunction Syndromes Syndrome, Hepatopulmonary Industries, Health Care Pregnanolone, (5alpha)-isomer Microbiome Paraplegia Androgen-Independent Prostatic Neoplasm

Professional Narrative

Dr. Henry Siegfried was born in DuBois, Pennsylvania and is a graduate of Villanova University. He obtained his medical degree at Thomas Jefferson University in Philadelphia. His residency was at Thomas Jefferson and its affiliated Wills Eye Hospital, and he completed his training with fellowships at the University of Connecticut incataract andcorneal surgery.

Dr. Siegfried has thirty years’ experience in ophthalmic surgery,withspecialinterestin cataract surgery,corneal transplantation,andlaserrefractiveprocedures.Heisa founding member of Precision LASIK Group, Chief of Ophthalmology at The Hospital ofCentral Connecticut,andco-medical director of the Connecticut eye bank.

Employment

Executive Director, Amgen 1999
Executive Director, Harvard Med 1992

Education

Doctor of medicine, Baylor College 2010
Doctor of osteopathic medicine, Yale School of Medicine 1999

Referees

Publications

Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020 Oct;19(10):673-694. doi: 10.1038/s41573-020-0075-7. Epub 2020 Aug 11. PMID: 32782413; PMCID: PMC7419031.

Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021 Feb;20(2):101-124. doi: 10.1038/s41573-020-0090-8. Epub 2020 Dec 4. PMID: 33277608; PMCID: PMC7717100.

Oberli MA, Reichmuth AM, Dorkin JR, Mitchell MJ, Fenton OS, Jaklenec A, Anderson DG, Langer R, Blankschtein D. Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. Nano Lett. 2017 Mar 8;17(3):1326-1335. doi: 10.1021/acs.nanolett.6b03329. Epub 2016 Dec 5. PMID: 28273716; PMCID: PMC5523404.

Reichmuth AM, Oberli MA, Jaklenec A, Langer R, Blankschtein D. mRNA vaccine delivery using lipid nanoparticles. Ther Deliv. 2016;7(5):319-34. doi: 10.4155/tde-2016-0006. Erratum in: Ther Deliv. 2016 Jun;7(6):411. PMID: 27075952; PMCID: PMC5439223.

Grants,Awards and Certifications

Grants :

No Grants Mentioned !!

Awards & Prizes :

Languages

Language Proficiency :

Translation Services :

Serving Millions of physicians and biomedical scientists in Industry and academia.

Site
Services
Follow Us
Contact Us
  • support@scienceandminds.com

Copyright © 2025 Trialect Inc. All rights reserved. | v2023.06.17.02